US States Slash Medicaid Coverage for Popular Obesity Drugs Amid Budget Strains

8 articles · Updated · The Guardian · Apr 14

Several US states, including California and Pennsylvania, have ended or restricted Medicaid coverage for GLP-1 anti-obesity drugs amid soaring costs.
Patients and healthcare advocates warn the move limits access to effective medications, particularly for low-income and minority communities disproportionately affected by obesity.
Officials cite unsustainable spending as the reason, but experts caution this may worsen long-term health outcomes and increase future healthcare costs.

With states restricting GLP-1s, are patients forced to become 'much sicker' before qualifying for coverage?

Can federal GLP-1 initiatives truly bridge the gap created by state coverage cuts and OBBBA's Medicaid reductions?

Given the HCV success, what specific price negotiation tactics can accelerate GLP-1 affordability and access in the US?

Will new oral GLP-1s and generic competition make these life-changing drugs affordable before 2030?

Could a 'subscription model' or value-based agreements with manufacturers offer a sustainable path for GLP-1 access?

Beyond cost, what are the ethical implications of denying effective chronic disease treatment to vulnerable populations?